Showing results (21-30 of 38) with videos related to
Sort By:
Pageof 4
Clinical Breast Cancer|October 9, 2007
Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancerEleni Andreopoulou, Darci Gaiotti, Eugene Kim, et al.Breast Cancer Research and Treatment|June 6, 2014
A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancerTadeu Ambros, Simon B Zeichner, John Zaravinos, et al.Breast Cancer : Basic and Clinical Research|April 30, 2015
Defining the survival benchmark for breast cancer patients with systemic relapseSimon B Zeichner, Tadeu Ambros, John Zaravinos, et al.Breast Cancer Research and Treatment|December 27, 2011
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancerHope S Rugo, A Jo Chien, Sandra X Franco, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III studyCharles L Vogel, Marek Z Wojtukiewicz, Robert R Carroll, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2023
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseMelody A Cobleigh, Charles L Vogel, Debu Tripathy, et al.The Oncologist|November 25, 2004
Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapyCharles L Vogel, Ronald H Yanagihara, Albert J Wood, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2008
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancerHenry L Gomez, Dinesh C Doval, Miguel A Chavez, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerCharles L Vogel, Melody A Cobleigh, Debu Tripathy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2023
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerCharles L Vogel, Melody A Cobleigh, Debu Tripathy, et al.Pageof 4